PA
MRTX

Parallel Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Parallel Advisors’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-124
Closed -$7.29K – 3463
2023
Q4 		$7.29K Sell
124
-2,182
-95% -$123K ﹤0.01% 2406
2023
Q3 		$100K Buy
2,306
+714
+45% +$25.5K ﹤0.01% 1083
2023
Q2 		$57.5K Buy
1,592
+179
+13% +$7.38K ﹤0.01% 1337
2023
Q1 		$52.5K Sell
1,413
-257
-15% -$11.6K ﹤0.01% 1355
2022
Q4 		$75.7K Buy
1,670
+546
+49% +$35.3K ﹤0.01% 1109
2022
Q3 		$79K Buy
1,124
+151
+16% +$11.2K ﹤0.01% 1067
2022
Q2 		$65K Buy
973
+602
+162% +$38.3K ﹤0.01% 1136
2022
Q1 		$31K Buy
371
+280
+308% +$28.6K ﹤0.01% 1526
2021
Q4 		$13K Buy
91
+65
+250% +$10.1K ﹤0.01% 2011
2021
Q3 		$5K Buy
26
+21
+420% +$3.38K ﹤0.01% 2403
2021
Q2 		$1K Sell
5
-18
-78% -$2.89K ﹤0.01% 2876
2021
Q1 		$4K Buy
23
+4
+21% +$792 ﹤0.01% 2307
2020
Q4 		$4K Buy
19
+13
+217% +$2.81K ﹤0.01% 2153
2020
Q3 		$1K Buy
+6
New +$821 ﹤0.01% 2521

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Parallel Advisors's MRTX Position: Q1 2024 in Review

Parallel Advisors sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 124 shares — an estimated $7.29K sold.

Parallel Advisors first reported a position in MRTX in Q3 2020 and held it in 14 quarters. The position peaked at $100K in Q3 2023. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Parallel Advisors reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Parallel Advisors sold 124 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $7.29K.
  • Parallel Advisors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2020 and held it in 14 quarters.
  • Parallel Advisors's Mirati Therapeutics, Inc. Common Stock position peaked at $100K in Q3 2023.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Parallel Advisors's 13F filing for Q1 2024, filed 6 May 2024.